India is facing a significant public health crisis with 254 million people living with generalised obesity and another 351 million affected by abdominal obesity. A recent study reveals that while 84% of Indians have attempted to lose weight at some point in time, only 4.7% managed to sustain even modest weight loss for a year.
Furthermore, over one-third of respondents have not consulted a healthcare professional regarding their weight in five years. This growing health challenge, linked to
nearly 6 lakh adult deaths in 2019, has triggered a surge in the obesity drug market.
Pharmaceutical major Cipla's 'Yurpeak' has gained significant traction alongside other drugs like Wegovy, Ozempic, and Mounjaro. The PharmaTrack report for January highlights these new entrants as 'blockbuster' introductions. The shift towards medical intervention reflects a growing desperation to manage weight as formal diagnoses remain low and obesity-related diseases rise across the country.